CLINICAL TRIALS PROFILE FOR RIVOGLITAZONE
✉ Email this page to a colleague
Clinical Trials for Rivoglitazone
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00143520 ↗ | Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes | Completed | Daiichi Sankyo Inc. | Phase 2/Phase 3 | This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison. |
NCT00143520 ↗ | Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes | Completed | Daiichi Sankyo, Inc. | Phase 2/Phase 3 | This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison. |
NCT00484198 ↗ | Study of Rivoglitazone in Type 2 Diabetes Mellitus | Completed | Daiichi Sankyo Inc. | Phase 3 | This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. |
NCT00484198 ↗ | Study of Rivoglitazone in Type 2 Diabetes Mellitus | Completed | Daiichi Sankyo, Inc. | Phase 3 | This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. |
NCT00571519 ↗ | Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Terminated | Daiichi Sankyo Inc. | Phase 3 | This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Participants who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments. |
NCT00571519 ↗ | Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Terminated | Daiichi Sankyo, Inc. | Phase 3 | This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Participants who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments. |
NCT00575471 ↗ | Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes | Completed | Daiichi Sankyo Co., Ltd. | Phase 2 | The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Rivoglitazone
Condition Name
Clinical Trial Locations for Rivoglitazone
Trials by Country
Clinical Trial Progress for Rivoglitazone
Clinical Trial Phase
Clinical Trial Sponsors for Rivoglitazone
Sponsor Name